Novruzov E, Peters H, Jannusch K, Kobbe G, Dietrich S, Fischer J
Eur J Radiol Open. 2025; 14():100619.
PMID: 39803388
PMC: 11719856.
DOI: 10.1016/j.ejro.2024.100619.
Linhares Y, Freytes C, Cherry M, Bachier C, Maris M, Hoda D
Blood Adv. 2024; 8(23):6114-6126.
PMID: 39347584
PMC: 11652776.
DOI: 10.1182/bloodadvances.2024013254.
Holland S, Sohal A, Nand A, Hutmacher D
Front Bioeng Biotechnol. 2024; 12:1413688.
PMID: 39175619
PMC: 11338886.
DOI: 10.3389/fbioe.2024.1413688.
Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske T, Farrukh F, Longo W
Blood Adv. 2024; 8(16):4320-4329.
PMID: 38889435
PMC: 11372811.
DOI: 10.1182/bloodadvances.2024013239.
Ferreri C, Bhutani M
Front Oncol. 2024; 14:1396490.
PMID: 38835382
PMC: 11148294.
DOI: 10.3389/fonc.2024.1396490.
The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?.
Knight E T, Oluwole O, Kitko C
Clin Hematol Int. 2024; 6(1):96-115.
PMID: 38817691
PMC: 11108586.
DOI: 10.46989/001c.94386.
Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations.
Gatwood K, Mahmoudjafari Z, Baer B, Pak S, Lee B, Kim H
Clin Hematol Int. 2024; 6(2):11-20.
PMID: 38817307
PMC: 11086991.
DOI: 10.46989/001c.115793.
Brave new world: expanding home care in stem cell transplantation and advanced therapies with new technologies.
Romon I, Gonzalez-Barrera S, Coello de Portugal C, Ocio E, Sampedro I
Front Immunol. 2024; 15:1366962.
PMID: 38736880
PMC: 11082320.
DOI: 10.3389/fimmu.2024.1366962.
The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review.
Hansen D, Liu Y, Ranjan S, Bhandari H, Potluri R, McFarland L
Cancers (Basel). 2023; 15(24).
PMID: 38136292
PMC: 10741664.
DOI: 10.3390/cancers15245746.
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bucklein V, Ingenerf M
Ann Hematol. 2023; 103(1):259-268.
PMID: 37861736
DOI: 10.1007/s00277-023-05507-9.
Telemedicine in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T Cell Therapy.
Gandhi A, Lee C
Cancers (Basel). 2023; 15(16).
PMID: 37627136
PMC: 10452361.
DOI: 10.3390/cancers15164108.
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.
Rejeski K, Hansen D, Bansal R, Sesques P, Ailawadhi S, Logue J
J Hematol Oncol. 2023; 16(1):88.
PMID: 37525244
PMC: 10391746.
DOI: 10.1186/s13045-023-01465-x.
Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.
Markouli M, Ullah F, Unlu S, Omar N, Lopetegui-Lia N, Duco M
Curr Oncol. 2023; 30(7):6330-6352.
PMID: 37504327
PMC: 10378049.
DOI: 10.3390/curroncol30070467.
Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries.
Canales Albendea M, Canonico P, Cartron G, Deiters B, Jommi C, Marks R
Front Med (Lausanne). 2023; 10:1128295.
PMID: 37324138
PMC: 10263061.
DOI: 10.3389/fmed.2023.1128295.
Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
Ahmed N, Wesson W, Mushtaq M, Porter D, Nasta S, Brower J
Transplant Cell Ther. 2023; 29(7):449.e1-449.e7.
PMID: 37120134
PMC: 11027185.
DOI: 10.1016/j.jtct.2023.04.019.
"I just wanted to speak to someone- and there was no one…": using Burden of Treatment Theory to understand the impact of a novel ATMP on early recipients.
Litchfield I, Calvert M, Kinsella F, Sungum N, Aiyegbusi O
Orphanet J Rare Dis. 2023; 18(1):86.
PMID: 37069697
PMC: 10111696.
DOI: 10.1186/s13023-023-02680-y.
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL.
Rejeski K, Blumenberg V, Iacoboni G, Lopez-Corral L, Kharboutli S, Hernani R
Hemasphere. 2023; 7(4):e858.
PMID: 37038465
PMC: 10082278.
DOI: 10.1097/HS9.0000000000000858.
Synthetic biology-inspired cell engineering in diagnosis, treatment, and drug development.
Zhao N, Song Y, Xie X, Zhu Z, Duan C, Nong C
Signal Transduct Target Ther. 2023; 8(1):112.
PMID: 36906608
PMC: 10007681.
DOI: 10.1038/s41392-023-01375-x.
CAR T cells: engineered immune cells to treat brain cancers and beyond.
Huang Z, Dewanjee S, Chakraborty P, Jha N, Dey A, Gangopadhyay M
Mol Cancer. 2023; 22(1):22.
PMID: 36721153
PMC: 9890802.
DOI: 10.1186/s12943-022-01712-8.
A digital platform for the design of patient-centric supply chains.
Triantafyllou N, Bernardi A, Lakelin M, Shah N, Papathanasiou M
Sci Rep. 2022; 12(1):17365.
PMID: 36253394
PMC: 9576774.
DOI: 10.1038/s41598-022-21290-5.
